Scholar Rock (NASDAQ:SRRK) Insider Mo Qatanani Sells 13,112 Shares

January 17, 2026 by InsiderTrades.com

Key Points

Mo Qatanani sold 13,112 shares on Jan. 14 at an average price of $45.20 (~$592,662), trimming his stake to 108,964 shares (a 10.74% reduction).
A cluster of mid‑January insider sales — including the CEO, COO and CFO — has added near‑term selling pressure and likely contributed to recent weakness in SRRK shares.
Despite the insider selling and a recent EPS miss, analysts are generally constructive (consensus Buy with an average price target of ~$50.14) and institutional investors own about 91.1% of the stock.

Scholar Rock Holding Corporation (NASDAQ:SRRK - Get Free Report) insider Mo Qatanani sold 13,112 shares of the stock in a transaction dated Wednesday, January 14th. The stock was sold at an average price of $45.20, for a total transaction of $592,662.40. Following the transaction, the insider directly owned 108,964 shares of the company's stock, valued at approximately $4,925,172.80. This trade represents a 10.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

3 Beaten-Down Stocks With Rebound Potential This Earnings Season

Mo Qatanani also recently made the following trade(s):

On Thursday, December 4th, Mo Qatanani sold 136,462 shares of Scholar Rock stock. The shares were sold at an average price of $45.21, for a total transaction of $6,169,447.02.

Scholar Rock Stock Performance

Shares of SRRK stock opened at $44.97 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.30 and a current ratio of 6.30. The firm has a market cap of $4.59 billion, a P/E ratio of -14.28 and a beta of 0.63. The firm's 50 day moving average price is $42.34 and its 200-day moving average price is $36.94. Scholar Rock Holding Corporation has a one year low of $22.71 and a one year high of $48.28.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last announced its earnings results on Friday, November 14th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.02). During the same quarter in the prior year, the firm earned ($0.66) earnings per share. As a group, equities research analysts predict that Scholar Rock Holding Corporation will post -2.42 EPS for the current year.

Wall Street Analyst Weigh In

SRRK has been the subject of several research reports. HC Wainwright dropped their target price on Scholar Rock from $50.00 to $44.00 and set a "buy" rating for the company in a research report on Tuesday, September 23rd. Cantor Fitzgerald reissued an "overweight" rating on shares of Scholar Rock in a research note on Thursday, December 11th. Weiss Ratings restated a "sell (d-)" rating on shares of Scholar Rock in a report on Wednesday, October 8th. Barclays upped their target price on shares of Scholar Rock from $45.00 to $52.00 and gave the stock an "overweight" rating in a research note on Wednesday, December 17th. Finally, Truist Financial decreased their price target on shares of Scholar Rock from $54.00 to $44.00 and set a "buy" rating for the company in a research report on Monday, October 20th. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Scholar Rock has an average rating of "Buy" and a consensus price target of $50.14.

Read Our Latest Analysis on SRRK

Trending Headlines about Scholar Rock

Here are the key news stories impacting Scholar Rock this week:

Positive Sentiment: Several sell-side firms have maintained or raised constructive ratings and price targets (consensus ~ $50+), which supports longer-term interest in the name. Analyst Coverage
Positive Sentiment: Large institutional positions and recent additions (e.g., Norges Bank, other funds) mean professional investors are committed to SRRK, which can support the share base despite short-term volatility. Institutional Holdings
Neutral Sentiment: Company fundamentals: Scholar Rock is a clinical-stage biotech focused on growth-factor biology (lead program SRK‑015 for SMA). It has strong liquidity metrics (high current/quick ratios), which reduces near‑term financing risk. Company Profile
Negative Sentiment: CEO David Hallal sold 57,450 shares at ~$42.70 on Jan 13 — a large single insider sale that can be interpreted negatively by the market. CEO Form 4
Negative Sentiment: COO Keith Woods sold 16,746 shares (~$42.70) on Jan 13. Aggregate exec selling increases perceived near-term supply pressure. COO Form 4
Negative Sentiment: CFO Vikas Sinha sold 16,755 shares (~$42.70) on Jan 13, and other insiders including Akshay Vaishnaw and Mo Qatanani also reduced positions in mid‑January — the cluster of senior-level sales is likely the main driver of today's weakness. CFO Form 4 Vaishnaw Form 4 Qatanani Form 4
Negative Sentiment: Prior quarterly EPS (Nov 14) missed estimates modestly, which keeps upside tied to clinical progress and future data rather than near-term earnings. Earnings Note

Institutional Trading of Scholar Rock

Hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC grew its holdings in Scholar Rock by 609.3% during the 1st quarter. AQR Capital Management LLC now owns 57,294 shares of the company's stock worth $1,842,000 after acquiring an additional 49,217 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Scholar Rock by 12.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,046 shares of the company's stock worth $1,709,000 after purchasing an additional 5,831 shares in the last quarter. Millennium Management LLC grew its stake in shares of Scholar Rock by 37.4% during the first quarter. Millennium Management LLC now owns 200,255 shares of the company's stock worth $6,438,000 after purchasing an additional 54,555 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Scholar Rock by 25.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company's stock valued at $5,460,000 after buying an additional 34,594 shares during the last quarter. Finally, Strs Ohio acquired a new stake in Scholar Rock in the first quarter valued at $77,000. Institutional investors and hedge funds own 91.08% of the company's stock.

About Scholar Rock

(Get Free Report)

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company's research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock's approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company's lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).